{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:27:27Z","timestamp":1767860847727,"version":"3.49.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis; DTaP5-HB-IPV-Hib vaccine: Diphtheria, tetanus, pertussis (5 acellular components: pertussis toxoid [PT], filamentous haemagglutinin [FHA], pertactin (PRN), and fimbriae Types 2 and 3 [FIM]), hepatitis B (recombinant DNA: rDNA), poliomyelitis (inactivated) and <jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> type b conjugate vaccine (adsorbed); MCM Vaccine B.V., The Netherlands] for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by <jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> type b. The comparator vaccine (control) was INFANRIX hexa (GlaxoSmithKline Biologics S.A., Rixensart, Belgium) (DTaP3-IPV-HepB\/Hib) in European studies and PENTACEL (DTaP5-IPV\/Hib) (Sanofi Pasteur, Swiftwater, PA) in US studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data from 6 studies were integrated and analyzed to provide a comprehensive safety profile. Numbers and proportions of subjects with adverse events (AEs) were summarized by treatment group. Group differences in proportion of AEs were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among the DTaP5-HB-IPV-Hib (N = 5223) and 2295 control (N = 2295) groups, solicited injection-site and systemic AEs were very common. Serious AEs were reported by 3.9% of DTaP5-HB-IPV-Hib and 3.7% of control subjects. Vaccine-related serious AEs occurred infrequently, 0.2% for both groups. Most AEs were mild-to-moderate and did not lead to subject withdrawal. Group differences for solicited systemic AEs were small (&lt;3%) and not statistically significant, except for pyrexia (estimated difference 9.4% [95% CI: 6.7%\u201312%]). The difference was driven by the 2 US studies where the PENTACEL control group had a lower fever rate. Among European studies, there was no significant difference in rates of pyrexia between DTaP5-HB-IPV-Hib and INFANRIX hexa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The safety of DTaP5-HB-IPV-Hib is consistent with the safety profile of its components and similar to comparator vaccines, including INFANRIX hexa. The vaccine provides a new, fully liquid and convenient hexavalent vaccination option for use with various vaccination schedules in Europe.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002257","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:32:06Z","timestamp":1543512726000},"page":"439-443","source":"Crossref","is-referenced-by-count":9,"title":["Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine"],"prefix":"10.1097","volume":"38","author":[{"given":"Jin","family":"Xu","sequence":"first","affiliation":[{"name":"From the Merck & Co., Inc., Kenilworth, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[{"name":"From the Merck & Co., Inc., Kenilworth, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy","family":"Ziani","sequence":"additional","affiliation":[{"name":"From the Merck & Co., Inc., Kenilworth, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Frank","family":"Liu","sequence":"additional","affiliation":[{"name":"From the Merck & Co., Inc., Kenilworth, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew W.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Merck & Co., Inc., Kenilworth, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1542\/peds.2014-4102","article-title":"Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants.","volume":"136","author":"Marshall","year":"2015","journal-title":"Pediatrics"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14760584.2017.1268920","article-title":"DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.","volume":"16","author":"Lee","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/INF.0b013e3182717edf","article-title":"Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.","volume":"32","author":"Tapi\u00e9ro","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.inf.0000437806.76221.20","article-title":"Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.","volume":"33","author":"Halperin","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/INF.0000000000001405","article-title":"Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants.","volume":"36","author":"Block","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/INF.0000000000001406","article-title":"A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months.","volume":"36","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","article-title":"A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.","volume":"34","author":"Silfverdal","year":"2016","journal-title":"Vaccine"},{"issue":"RR-3","key":"R13-20230912","first-page":"1","article-title":"Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Marin","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/01.inf.0000232635.81312.06","article-title":"The impact of DTaP-IPV-HB vaccine on use of health services for young infants.","volume":"25","author":"Thompson","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"e1179","DOI":"10.1542\/peds.2008-1977","article-title":"A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.","volume":"122","author":"Zangwill","year":"2008","journal-title":"Pediatrics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201904000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:33:12Z","timestamp":1694557992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201904000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002257","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}